

## ASX Announcement

### Human Ethics Approval Received for Phase 1 RC220 Trial at Gosford and Wyong Hospitals

- Gosford & Wyong Hospitals (Central Coast Local Health District) have received approval from the Bellberry Human Research Ethics Committee (HREC) to participate in the Phase 1 trial of RC220 in combination with doxorubicin
  - Central Coast Local Health District is the second site to receive HREC approval
  - Ethics approval allows both Gosford and Wyong Hospitals to enrol patients subject to final site approvals and activation.
- 

**31 March 2025** – Race Oncology Limited ('Race') is pleased to announce that it has received HREC approval from Bellberry to commence its RC220 Phase 1 clinical trial at Gosford and Wyong Hospitals (Central Coast Local Health District). HREC approval allows both the Gosford and Wyong Hospitals to enrol patients subject to final site approvals and activation. These approvals are expected during the month of April.

The RAC-010 clinical trial is designed to assess the safety, tolerability and pharmacokinetics (PK) of RC220 alone and in combination with doxorubicin, in patients with solid tumours.

This approval follows recent HREC approval for the Southside Cancer Centre (Miranda) (ASX Announcement: 14 March 2025). It is expected HREC approval will be received for additional trial sites in Australia, Hong Kong and South Korea over the following months.

Race also wishes to update investors on the site activation process at the Southside Cancer Centre. Final contracts terms have been agreed by both parties with final contract signing and site activation expected in the coming days.

**Race Chief Executive Officer & Managing Director, Dr. Daniel Tillett commented:** *"Receiving our second human ethics approval for our RC220 trial so soon after our first approval is both highly encouraging and a testament to the dedication of the team at Race. Once again, I wish to thank the Bellberry HREC and the entire Race and George Clinical teams for all their efforts in reaching this milestone."*

**Race Chief Medical Officer, Dr. Michelle Rashford commented:** *"This second ethics approval provides Race with further momentum for the study and in bringing RC220 to cancer patients."*

## Q&A

### What are the next steps for enabling these two hospital sites?

Institutional approval and activation of the sites by George Clinical will enable recruitment.

### How long will it take to activate the other trial sites?

Race expects that most Australian sites will be activated by George Clinical in Q1 or Q2 CY2025. As Hong Kong and South Korean sites have a longer regulatory review process, ethics approval is expected in Q3 2025.

### What is required for a cancer patient to enter the trial?

Patients who are under the care of the clinical trial study doctors at recruiting trial sites can discuss their interest in participation and potential eligibility with their treating doctor.

Patients being treated outside of the recruiting trial sites should discuss their interest in the trial with their treating oncologist for potential referral to the trial study doctor of one of the recruiting trial sites.

All patients will need to understand the trial requirements and provide informed consent to participate. They will then be reviewed and assessed by the study doctor and clinical trial team to determine whether the trial is suitable for them and whether they meet all the eligibility criteria to be enrolled on the trial.

### Where can I find out more information about the RC220 trial?

The details of the trial, including open and recruiting sites, are outlined and available on the public clinical trial registry: <https://clinicaltrials.gov/study/NCT06815575>. Further information is also available on the Race Oncology website.

Enquiries can be directed via email to Race Oncology at [trials@raceoncology.com](mailto:trials@raceoncology.com).

-ENDS-

## About Gosford and Wyong Hospitals

Central Coast Local Health District (CCLHD) provides high quality public healthcare to the Central Coast community through a network of hospitals, including Gosford and Wyong hospitals, healthcare centres and other community-based services.

CCLHD is focused on providing the community with care they trust and that matters most to them, to enable everyone to enjoy fulfilling lives.

As the largest employer in the Central Coast region, CCLHD supports a growing and ageing population of over 350,000 people with one of the fastest growing Aboriginal populations in the country.

CCLHD is committed to developing and supporting its people to drive innovation and collaboration that supports the delivery of exceptional care.

## About George Clinical

George Clinical is a globally recognised clinical research organisation (CRO) with over 20 years of experience designing and managing clinical trials. With a robust presence across Asia-Pacific, the United States, Europe, and beyond, George Clinical is known for delivering operational excellence supported by deep scientific expertise. George Clinical provides expert guidance, underscoring its commitment to advancing medical research through innovative, patient-focused approaches.

## About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, bisantrene, is a small molecule anticancer drug. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect with less cardiotoxicity compared to anthracyclines such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anticancer activity in solid tumours. Race is also exploring RC220 as a low-intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m<sup>6</sup>A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m<sup>6</sup>A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers.

Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at [www.raceoncology.com](http://www.raceoncology.com).

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

*Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at [www.automicgroup.com.au](http://www.automicgroup.com.au).*

### Release authorised by:

Daniel Tillett, CEO  
[info@raceoncology.com](mailto:info@raceoncology.com)

### Media contact:

Jane Lowe +61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)